Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03199794 · ClinicalTrials.gov registry record

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

A clinical trial, sponsored by Baxalta now part of Shire.

Completed
Registry status
50
Enrollment target

NCT03199794: Completed study, sponsored by Baxalta now part of Shire.

NCT03199794 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03199794 has completed, sponsored by Baxalta now part of Shire.

COMPLETED
Registry status
50 participants
Enrollment target

Study Summary

The study addresses the safety, utilisation and effectiveness of Obizur in the treatment of bleeding episodes in real-life clinical practice in Europe and the United States.

Primary Outcome

AE - adverse event, SAE - serious adverse event.

Interventions

  • BIOLOGICAL OBIZUR

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2016-12-14
Est. Completion 2021-07-30
Baxalta now part of Shire

74 total trials

What the finished NCT03199794 record still lists

NCT03199794 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which OBIZUR is the first listed.

NCT03199794 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03199794 about?

NCT03199794 is a clinical study titled "Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice". The study addresses the safety, utilisation and effectiveness of Obizur in the treatment of bleeding episodes in real-life clinical practice in Europe and the United States.

What is the current status of trial NCT03199794?

This trial is currently completed. The enrollment target is 50 participants. The study started on 2016-12-14. Estimated completion is 2021-07-30.

What interventions are being tested in trial NCT03199794?

The interventions under investigation include: OBIZUR (BIOLOGICAL).

Who is sponsoring clinical trial NCT03199794?

This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03199794, the US trial registry maintained by the National Library of Medicine. NCT03199794 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.